[A means of more physiological hormonal contraception] Ein Weg zu einer mehr physiologischen hormonalen Kontrazeption.
Clinical experience with the new sequential preparation Biogest (.07 5 mg mestranol for 11 days, .075 mg mestranol and 1 mg chlorsuperlutin for 10 days) in 597 women (5372 cycles) is reported. Side effects included gastrointestinal upsets (4%) and water retention (1%). No hepatic, circulatory, or oncologic complications were seen. Effectiveness was comparable to that of Stediril and Metrulen. Tests of a variant containing bromsuperlutin were also carried out. Breakthrough bleeding was much less frequent with Biogest than with other tested preparations.